Geisinger Health System’s $0 co-pay drug program for its chronically ill employee population is associated with positive cost savings and a 5-year return-on-investment of approximately 1.8.
James M. Pitcavage, MSPH
Advertisement
Articles by James M. Pitcavage, MSPH
Advertisement
Latest Updated Articles
- The Value of Value-Based Insurance Design: Savings From Eliminating Drug Co-Payments
Published: February 16th 2016 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
2
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
3
Mediterranean Diet Improves Psoriasis Severity, Study Finds
4
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
5
